Advice
In the absence of a submission from the holder of the marketing authorisation:
axicabtagene ciloleucel (Yescarta®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice234KB (PDF)
Medicine details
- Medicine name:
- axicabtagene ciloleucel (Yescarta)
- SMC ID:
- SMC2646
- Indication:
Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 15 January 2024